Smart Drug Development & Design from Candidate to Phase I

    This event will focus on key considerations for transitioning a molecule from discovery to phase 1 readiness including API and formulation development, pharmacokinetics, quality and CMC requirements, and incorporation of clinical supply services solutions to meet protocol, clinical site and patient needs.

    Following the meeting, all Catalent speakers and executives will be available for private, no-obligation discussions on specific programmes and challenges. To request an appointment, please contact Annalisa Zuccotti (az@biorn.org).

     

    9:00 am Registration

    9:30 am WELCOME & INTRODUCTION

    9.45 am "FORMULATION APPROACHES FOR POORLY SOLUBLE DRUG"- by Bernd Liepold, Senior Principal Research Scientist, AbbVie

    10.30 am "MODELING THE PHARMACOKINETIC CHALLENGES OF ORAL SMALL MOLECULE DRUGS" by Dr. Jan Neelissen, Catalent Pharma Solutions

    11.15 am "IMPORTANCE OF API CHARACTERIZATION IN OVERCOMING KEY FORMULATION CHALLENGES FOR SMALL MOLECULE" by Dr. Rob Harris, Catalent Nottingham

    12 pm Lunch

    1 pm "INTEGRATING QUALITY AND CMC INTO EARLY DEVELOPMENT" by Dr. David Elder, Principal Consultant

    1.45 pm "STRATEGIC CLINICAL SUPPLY SOLUTIONS FOR EARLY PHASE CLINICAL TRIAL" by Dr. Carsten Schmidt, Grünenthal Innovation

    2.15 pm Concluding remarks and meet the experts

    Download here the final program!

Share

Or share this link:

Export

Information

  • Directions

    Event venue address

    Conference Center - Technology Park Heidelberg Im Neuenheimer Feld 582 69120 Heidelberg Germany
    Wheelchair friendly Unknown
  • More events

    • BioRN Lounge - October
      Urban Kitchen
      29 October 2019 19:00
      Registration
    • BioRN Annual Conference
      DKFZ - Communication Center
      11 November 2019 09:30
      Registration
powered by XING Events

Event organiser: BioRN Network e.V.
More participants thanks to online event management solutions from XING Events.

Imprint